Akums Drugs and Pharmaceuticals shareholders and shareholding pattern
NSE: AKUMSBSE: 544222Pharmaceuticals & BiotechnologySmall Cap
Akums Drugs and Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2024 · Issue price ₹679
Last close ₹741.05up ₹18.35 (2.54%)BSE ₹741.10
Share price at the NSE close on 29 Oct 2026. Previous close ₹722.70.
29 Oct: open ₹717.60, high ₹745.00, low ₹714.85
52-week range of traded prices to 29 Oct 2026
₹409.30Low, 21 Jan 2026₹838.80High, 23 Sep 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹11,664 Cr630th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.98
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.52
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.40%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,10,47256.9% delivered
Akums Drugs and Pharmaceuticals' shareholding pattern for Sep 2026, filed on 12 Oct 2026, with every filing from Sep 2024: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Akums Drugs and Pharmaceuticals, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters75.26%
- Foreign institutions4.50%
- Indian institutions11.08%
- Individuals and others6.43%
- Employee trusts2.73%
Shareholding pattern, per cent
- Promoters
- Foreign institutions
- Indian institutions
- Individuals and others
- Employee trusts
| Per cent | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|
| 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | |
| Indian promoters | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 22.01% | 22.01% | 22.01% | 22.01% | 22.01% | 22.01% | 22.01% | 22.01% | 22.01% |
| Employee trusts | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% |
| Shares in issue | 15,73,93,988 | 15,73,93,988 | 15,73,93,988 | 15,73,93,988 | 15,73,93,988 | 15,73,93,988 | 15,73,93,988 | 15,73,93,988 | 15,73,93,988 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 13,18,36,871 | 12,57,33,915 | 3,14,78,800 | 3,14,78,800 | 3,14,78,800 | 3,14,78,800 | – | – | – |
| Promoters' shares locked in | 11,84,55,380 | 11,84,55,380 | 3,14,78,800 | 3,14,78,800 | 3,14,78,800 | 3,14,78,800 | – | – | – |
A dash is a line the filing did not state. “Under 0.01%” is a holding of shares too small to show at two decimals.
Akums Drugs and Pharmaceuticals promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is AKUMS MASTER TRUST (Sanjeev Jain and Sandeep Jain), 40.79%. The filing names 26 more members with no shares.Promoter buying and selling
| Holder | ||
|---|---|---|
| AKUMS MASTER TRUST (Sanjeev Jain and Sandeep Jain)Indian companies, trusts and others | 40.79% | 6,42,00,000 |
| Sandeep JainIndividuals and Hindu undivided families | 17.24% | 2,71,27,690 |
| Sanjeev JainIndividuals and Hindu undivided families | 17.23% | 2,71,13,940 |
| Lata JainIndividuals and Hindu undivided families | 0.01% | 13,750 |
No promoter shares are reported as pledged.
Largest public holders of Akums Drugs and Pharmaceuticals, filing by filing
Per cent, on the same shares as the split above.Mutual funds holding Akums Drugs and Pharmaceuticals
| Holder | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Clarus Capital IAlternative investment funds | – | – | – | – | 1.30% | 1.80% | 1.96% | 2.17% | 2.23% |
| Ruby Qc Investment Holdings Pte LtdForeign companies | 4.62% | 4.62% | 4.62% | 4.62% | 4.62% | – | – | – | – |
| Smallcap World Fund, IncForeign portfolio investors, category I | 2.15% | 2.15% | 1.69% | – | – | – | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. Mutual funds are left out here: each fund's holding is on the Mutual funds tab, from its own portfolio. A dash is a filing that did not name the holder, which includes holding under one per cent.
Who moved in the Sep 2026 filing
Against the Jun 2026 filing. A filing names a public holder only at 1% or more, so a holder no longer named fell under 1% or sold out.
- Indian institutions: Clarus Capital I 2.23%, +0.06 pts